NCT07905924
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants with advanced solid tumors (second line or higher \[2L+\]) with a RAS G12V mutation will receive increasing doses of RO7836748.
Participants with (2L+) NSCLC, PDAC, and CRC with a RAS G12V mutation will receive the selected doses of RO7836748 at sponsor's discretion Some participants enrolled may also participate in a food effect assessment and/or a drug-drug interaction (DDI) investigation, if necessary.
Participants with 2L+ NSCLC, PDAC, and CRC with a RAS G12V mutation will receive RO7836748 at the dose selected based on findings from Part 1A and 1B.
Participants with untreated advanced (first line treatment \[1L+\]) or metastatic NSCLC with a KRAS G12V mutation and programmed death-ligand (PD-Ll ) tumor cell expression levels ≥ 1% will receive RO7836748 in combination with pembrolizumab at the dose selected based on findings from Parts 1 and 2.
Participants with untreated advanced (1L) or metastatic PDAC will receive RO7836748 in combination with mFOLFIRINOX at the dose selected based on findings from Parts 1 and 2.
Participants with CRC after second line/ third line (2L/3L) treatment will receive RO7836748 in combination with cetuximab at the dose selected based on findings from Parts 1 and 2.
Drugs: RO7836748, Pembrolizumab, mFOLFIRINOX, Cetuximab